51. Src Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases.
- Author
-
Siyuan Zhang, Wen-Chien Huang, Lin Zhang, Chenyu Zhang, Lowery, Frank J., Zhaoxi Ding, Hua Guo, Hai Wang, Suyun Huang, Sahin, Aysegul A., Aldape, Kenneth D., Steeg, Patricia S., and Dihua Yu
- Subjects
- *
BREAST cancer treatment , *CANCER invasiveness , *CELL lines , *BRAIN cancer , *CELL cycle - Abstract
Despite better control of early-stage disease and improved overall survival of patients with breast cancer, the incidence of life-threatening brain metastases continues to increase in some of these patients. Unfortunately, other than palliative treatments there is no effective therapy for this condition. In this study, we reveal a critical role for Src activation in promoting brainmetastasis in a preclinical model of breast cancer and we show how Src-targeting combinatorial regimens can treat HER2+ brain metastases in this model. We found that Src was hyperactivated in brain-seeking breast cancer cells derived from human cell lines or from patients' brain metastases. Mechanistically, Src activation promoted tumor cell extravasation into the brain parenchyma via permeabilization of the blood--brain barrier. When combined with the EGFR/HER2 dual-targeting drug lapatinib, an Src-targeting combinatorial regimen prevented outgrowth of disseminated breast cancer cells through the induction of cell-cycle arrest. More importantly, this combinatorial regimen inhibited the outgrowth of established experimental brain metastases, prolonging the survival of metastases-bearing mice. Our results provide a rationale for clinical evaluation of Src-targeting regimens to treat patients with breast cancer suffering from brain metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF